TrianglePersonalized TMV Tumor Vaccine (NCT06324240)
Personalized TMV Tumor Vaccine trial for Triple-Negative Breast Cancer (NCT06324240). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for triple negative breast cancer, in adults.
The idea: a personalized vaccine. It is made from a piece of the patient's own tumor, to stimulate the immune system's memory. Patients receive the TMV vaccine at weeks 1, 3 and 5, first alone, then with a checkpoint inhibitor, pembrolizumab or ipilimumab.
This phase 1 trial plans 18 patients and studies safety and the best dose. At Emory University Hospital and Winship Cancer Institute in Atlanta, Keerthi Gogineni leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.